- Investing.com
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Metrics to compare | SERA | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipSERAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −1.7x | −0.5x | |
PEG Ratio | −0.22 | −0.03 | 0.00 | |
Price/Book | 1.0x | 4.3x | 2.6x | |
Price / LTM Sales | 848.5x | 37.4x | 3.3x | |
Upside (Analyst Target) | - | 285.7% | 43.5% | |
Fair Value Upside | Unlock | 25.0% | 6.3% | Unlock |